

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane, which is indicated in the treatment of primary systemic carnitine deficiency.
Product Name : Carnitor-Generic
Product Type : Amino Acid
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
Details : ANI’s Levocarnitine Tablets are the generic version of the Reference Listed Drug (RLD) Carnitor®. The launch of Levocarnitine Tablets is another example of ANI’s commitment to increasing patient access to affordable, high-quality medicines.
Product Name : Levocarnitine-Generic
Product Type : Amino Acid
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Levocarnitine
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyperthyroidism: Methimazole Plus L-carnitine and Selenium
Details : L-Carnitine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hyperthyroidism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : Levocarnitine
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Levocarnitine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Instituto Nacional de Salud Publica, Mexico
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
Details : L-Carnitine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2018
Lead Product(s) : Levocarnitine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Instituto Nacional de Salud Publica, Mexico
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Levocarnitine
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Role of Nutritional Support in Idiopathic Male Infertility
Details : L-Carnitine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Infertility, Male.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 17, 2018
Lead Product(s) : Levocarnitine
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Levocarnitine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Hanmi Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : L-Carnitine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastrointestinal Stromal Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2018
Lead Product(s) : Levocarnitine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Hanmi Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levocarnitine
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Carnipure® Tartrate on Postprandial Endothelial Function and Recovery
Details : L-Carnitine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2015
Lead Product(s) : Levocarnitine
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Levocarnitine
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Ildong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of L-carnitine on Hypothyroidism
Details : L-Carnitine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypothyroidism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2013
Lead Product(s) : Levocarnitine
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Ildong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levocarnitine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Clinical Study of the Efficacy and Safety of L-Carnitine Injection in Treatment of Heart Failure
Details : Levocarnitine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
April 19, 2012
Lead Product(s) : Levocarnitine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Levocarnitine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : L-Carnitine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Postpoliomyelitis Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2012
Lead Product(s) : Levocarnitine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
